A client with a organ transplant has been placed on methotrexate (Rheumatrex). Which of the following mechanism of actions below describes this medication?

A) Inhibits helper T Cells: While methotrexate does have an immunosuppressive effect, it does not directly inhibit helper T cells. Instead, it primarily acts by inhibiting the folic acid pathway, which is necessary for DNA and RNA synthesis. This action affects rapidly dividing cells, including those in the immune system, but its mechanism is not specifically focused on inhibiting T cells. Therefore, this is not the most accurate description of methotrexate’s action. B) Inhibits replication by blocking folic acid synthesis: Methotrexate is a folic acid antagonist that works by inhibiting the enzyme dihydrofolate reductase (DHFR). This inhibition disrupts the conversion of folic acid into its active form (tetrahydrofolate), which is crucial for purine and pyrimidine synthesis necessary for DNA and RNA replication. This action limits the replication of cells, including immune cells, which is beneficial in conditions such as organ transplantation, where immune suppression is necessary to prevent rejection. This mechanism is central to methotrexate's use in both cancer treatment and immunosuppressive therapy for organ transplants. C) Prevents DNA and RNA synthesis: While it is true that methotrexate affects DNA and RNA synthesis, this statement is too broad and not as specific as the correct answer. The drug works by blocking folic acid metabolism, which in turn affects the synthesis of DNA and RNA, but it is the inhibition of folic acid synthesis (as described in option B) that is the most accurate mechanism of action. Other drugs, such as antimetabolites, may also prevent DNA and RNA synthesis through different mechanisms. D) Estrogen blocker: Methotrexate is not an estrogen blocker. It has no direct effect on estrogen receptors or the endocrine system in a way that would block estrogen action. Estrogen blockers (e.g., tamoxifen) are used in the treatment of hormone receptor-positive breast cancer, but methotrexate is an immunosuppressant and antimetabolite with no significant role in estrogen receptor modulation. Therefore, this is an incorrect description of methotrexate’s mechanism.